LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Corcept Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

73.21 -1.43

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

72.52

Max

75.47

Schlüsselkennzahlen

By Trading Economics

Einkommen

-9.8M

21M

Verkäufe

-25M

157M

KGV

Branchendurchschnitt

64.591

50.291

EPS

0.169

Gewinnspanne

13.069

Angestellte

500

EBITDA

-22M

3.4M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+87.45% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

28. Juli 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

165M

7.9B

Vorheriger Eröffnungskurs

74.64

Vorheriger Schlusskurs

73.21

Nachrichtenstimmung

By Acuity

49%

51%

157 / 380 Ranking in Healthcare

Corcept Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

27. Juni 2025, 20:51 UTC

Ergebnisse

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27. Juni 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27. Juni 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27. Juni 2025, 20:48 UTC

Market Talk

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27. Juni 2025, 20:46 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

27. Juni 2025, 20:46 UTC

Market Talk

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27. Juni 2025, 19:31 UTC

Market Talk

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27. Juni 2025, 19:19 UTC

Market Talk

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27. Juni 2025, 19:16 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27. Juni 2025, 18:57 UTC

Akquisitionen, Fusionen, Übernahmen

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27. Juni 2025, 18:57 UTC

Akquisitionen, Fusionen, Übernahmen

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27. Juni 2025, 18:57 UTC

Akquisitionen, Fusionen, Übernahmen

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27. Juni 2025, 18:57 UTC

Akquisitionen, Fusionen, Übernahmen

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27. Juni 2025, 18:57 UTC

Akquisitionen, Fusionen, Übernahmen

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27. Juni 2025, 18:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. Juni 2025, 18:42 UTC

Market Talk

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27. Juni 2025, 18:39 UTC

Market Talk
Ergebnisse

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27. Juni 2025, 18:29 UTC

Market Talk

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27. Juni 2025, 18:18 UTC

Market Talk

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27. Juni 2025, 18:16 UTC

Market Talk

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27. Juni 2025, 17:16 UTC

Market Talk

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27. Juni 2025, 17:08 UTC

Ergebnisse

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27. Juni 2025, 16:52 UTC

Akquisitionen, Fusionen, Übernahmen

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27. Juni 2025, 16:22 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27. Juni 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

27. Juni 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27. Juni 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

27. Juni 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

27. Juni 2025, 15:59 UTC

Market Talk

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27. Juni 2025, 15:56 UTC

Market Talk

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Peer-Vergleich

Kursveränderung

Corcept Therapeutics Inc Prognose

Kursziel

By TipRanks

87.45% Vorteil

12-Monats-Prognose

Durchschnitt 139.33 USD  87.45%

Hoch 145 USD

Tief 131 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Corcept Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

4

Buy

0

Halten

0

Sell

Stimmung

By Acuity

157 / 380 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.